Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Actavis Inc    

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

WATSON PHARM : Watson Confirms Court Decision Rejecting Teva's Motion to Prevent Launch of Generic SEASONIQUE®

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/17/2011 | 02:00pm CET

PARSIPPANY, N.J., June 17, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading integrated global pharmaceutical company, today confirmed that the United States District Court for the District of Nevada denied Duramed Pharmaceuticals, Inc.'s request for a preliminary injunction and request for a temporary restraining order preventing Watson's launch of generic SEASONIQUE® (levonorgestrel/ethinyl estradiol (0.15 mg/0.03 mg) and ethinyl estradiol (0.01 mg). The company is evaluating plans to launch the contraceptive product.

On March 25, 2011, Watson received a favorable decision from the United States Court of Appeals for the Federal Circuit that reversed and remanded for trial a March 31, 2010 summary judgment order from the United States District Court for the District of Nevada regarding United States Patent No. 7,320,969 (the '969 patent).

On January 22, 2008, Watson notified Teva Women's Health that Watson's ANDA contained a paragraph IV certification asserting that the '969 patent is invalid, unenforceable and/or not infringed.

SEASONIQUE® is indicated for the prevention of pregnancy.

SEASONIQUE® is a registered trademark of Teva Women's Health, Inc.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the difficulty of predicting the timing and outcome of the pending patent litigation and risks that an adverse outcome in such litigation could render Watson liable for substantial damages; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's quarterly report on form 10-Q for the quarter ended March 31, 2011 and Watson's annual report on Form 10-K for the year ended December 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)


    CONTACTS:       Investors:
                    Patty Eisenhaur
                    (862) 261-8141

                    Media:
                    Charlie Mayr
                    (862) 261-8030

SOURCE Watson Pharmaceuticals, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ACTAVIS INC
01/18DJAllergan Admits to Disclosure Violations During Valeant Bid
01/17 Allergan to pay $15 million over failing to disclose merger talks
01/10DJValeant Agrees To Sell Dendreon -- WSJ
01/03DJAfter Slower Year, Deal Prospects Set to Brighten -- WSJ
2016 Actavis UK raised drug prices 12,000 percent, watchdog finds
2016 U.S. states sue Mylan, Teva, others for fixing drug prices
2016DJMARKET SNAPSHOT : S&P 500, Dow Hit Intraday Records, On Track For Weekly Gains
2016DJCorrection to Novo Nordisk Pledges to Limit Price Increases in US for Its Dru..
2016DJNovo Nordisk Pledges to Limit Price Increases in U.S. for Its Drugs
2016DJNovo Nordisk Pledges to Limit Price Increases in U.S. for Its Drugs
More news
Sector news : Pharmaceuticals - NEC
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
01/19 Davos CEOs 'go local' on supply chain in Trump era
01/19 GSK grabs Astra executive to replace pharma head
01/19DJGLAXOSMITHKLINE : Global Pharmaceuticals President Abbas Hussain to Leave -- Upd..
More sector news : Pharmaceuticals - NEC